Solidcore Resources passes all resolutions at its 2025 annual general meeting

Vitaly Nesis Chief Executive Officer Polymetal International
Vitaly Nesis Chief Executive Officer - Polymetal International
0Comments

Solidcore Resources plc held its Annual General Meeting (AGM) on May 21, 2025, at 2:30 p.m. Astana time. At the meeting, all resolutions proposed by the Directors in the Notice of the AGM dated April 24, 2025, were approved by shareholders.

Among the resolutions passed were the approval of the annual report and accounts, with 91.71% voting in favor and 8.29% against. The remuneration report received strong support as well, with 99.93% voting for and only 0.07% against.

Shareholders also voted on board appointments and reappointments. Vitaly Nesis was re-appointed to the board with 99.45% in favor, while Omar Bahram’s re-appointment received 98.90% support. Other directors re-elected included Evgueni Konovalenko (98.83%), Janat Berdalina (99.84%), Steven Dashevsky (98.23%), Pascale Jeannin Perez (94.90%), and Richard Sharko (99.44%). Abdulmonem Al-Murshidi was newly elected to the board with a majority of 99.40%.

Ernst & Young LLP was re-appointed as auditors with nearly unanimous support—99.95% in favor—and their remuneration was also approved by a majority of shareholders.

Additional resolutions addressed share allotment authority, treasury shares, market purchases, and reduction of capital—all passing with substantial majorities.

The company noted that it holds over 87 million ordinary shares in treasury without voting or economic rights, bringing total voting rights in Solidcore Resources to just under 474 million.

According to Solidcore Resources’ announcement, “all resolutions proposed by the Directors in the Notice of the AGM dated 24 April 2025 were duly passed with the results as stated below.”

Votes withheld are not counted towards votes for or against any resolution.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.